John A. Christopher
John A. Christopher has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
James C. Errey
Sosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.
6 shared publicationsAndrew S. Doré
Sosei Heptares , Steinmetz Building, Granta Park , Cambridge CB21 6DG , U.K.
4 shared publications- Fiona H. Marshall
Heptares Therapeutics Ltd, Biopark, Welwyn Garden City, Hertfordshire, AL7 3AX, UK
4 shared publications Giles A. Brown
Sosei Heptares, Steinmetz Building, Granta Park, Great Abington, Cambridge CB21 6DG, U.K.
4 shared publicationsMiles Congreve
Heptares Therapeutics Ltd. , BioPark , Welwyn Garden City , Hertfordshire AL7 3AX , U.K.
4 shared publications- Miles Congreve
Sosei Heptares, Steinmetz Building, Granta Park, Great Abington, Cambridge CB21 6DG, U.K.
4 shared publications
Latest Publications
- 4 March 2022
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 13 (6) , 751-765
Novel Macrocyclic Antagonists of the Calcitonin Gene-Related Peptide Receptor: Design, Realization, and Structural Characterization of Protein–Ligand Complexes
A series of macrocyclic calcitonin gene-related peptide (CGRP) receptor antagonists identified using structure-based design principles, exemplified by HTL0028016 (1) and HTL0028125 (2), is described. Structural characterization by X-ray crystallography of the interaction of two of the macrocycle antagonists with the CGRP receptor ectodomain is described, along with structure–activity relationships associated with point changes to the macrocyclic antagonists. The identification of non-peptidic/natural product-derived, macrocyclic ligands for a G protein coupled receptor (GPCR) is noteworthy.
- 4 March 2022
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 13 (6) , 751-765
Novel Macrocyclic Antagonists of the Calcitonin Gene-Related Peptide Receptor: Design, Realization, and Structural Characterization of Protein–Ligand Complexes
A series of macrocyclic calcitonin gene-related peptide (CGRP) receptor antagonists identified using structure-based design principles, exemplified by HTL0028016 (1) and HTL0028125 (2), is described. Structural characterization by X-ray crystallography of the interaction of two of the macrocycle antagonists with the CGRP receptor ectodomain is described, along with structure–activity relationships associated with point changes to the macrocyclic antagonists. The identification of non-peptidic/natural product-derived, macrocyclic ligands for a G protein coupled receptor (GPCR) is noteworthy.
- Open Access
- 20 December 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (4) , 1528-1543
Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis
The orexin system, which consists of the two G protein-coupled receptors OX1 and OX2, activated by the neuropeptides OX-A and OX-B, is firmly established as a key regulator of behavioural arousal, sleep and wakefulness, and has been an area of intense research effort over the past two decades. X-ray structures of the receptors in complex with ten new antagonist ligands from diverse chemotypes are presented, which complement the existing structural information for the system and highlight the critical importance of lipophilic hotspots and water molecules for these peptidergic GPCR targets. Learnings from the structural information regarding the utility of pharmacophore models and how selectivity between OX1 and OX2 can be achieved are discussed.
- 20 December 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (4) , 1528-1543
Open AccessComparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis
The orexin system, which consists of the two G protein-coupled receptors OX1 and OX2, activated by the neuropeptides OX-A and OX-B, is firmly established as a key regulator of behavioural arousal, sleep and wakefulness, and has been an area of intense research effort over the past two decades. X-ray structures of the receptors in complex with ten new antagonist ligands from diverse chemotypes are presented, which complement the existing structural information for the system and highlight the critical importance of lipophilic hotspots and water molecules for these peptidergic GPCR targets. Learnings from the structural information regarding the utility of pharmacophore models and how selectivity between OX1 and OX2 can be achieved are discussed.
- 2 October 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (3) , 905-927
Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors
Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are proglucagon derived peptides that are released from gut endocrine cells in response to nutrient intake. These molecules are rapidly inactivated by the action of dipeptidyl peptidase IV (DPP-4) which limit their use as therapeutic agents. The recent emergence of three-dimensional structures of G protein coupled receptors (GPCR) such as GLP-1R and glucagon receptor has helped to drive the rational design of innovative peptide molecules that hold promise as novel peptide therapeutics. One emerging area is the discovery of multifunctional molecules that act at two or more pharmacological systems to enhance therapeutic efficacy. In addition, drug discovery efforts are also focusing on strategies to improve patient convenience through alternative routes of peptide delivery. These novel strategies highlight the broad utility of peptide-based therapeutics in human disease settings where unmet needs still exist.
- 2 October 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (3) , 905-927
Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors
Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are proglucagon derived peptides that are released from gut endocrine cells in response to nutrient intake. These molecules are rapidly inactivated by the action of dipeptidyl peptidase IV (DPP-4) which limit their use as therapeutic agents. The recent emergence of three-dimensional structures of G protein coupled receptors (GPCR) such as GLP-1R and glucagon receptor has helped to drive the rational design of innovative peptide molecules that hold promise as novel peptide therapeutics. One emerging area is the discovery of multifunctional molecules that act at two or more pharmacological systems to enhance therapeutic efficacy. In addition, drug discovery efforts are also focusing on strategies to improve patient convenience through alternative routes of peptide delivery. These novel strategies highlight the broad utility of peptide-based therapeutics in human disease settings where unmet needs still exist.
- 1 October 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (20) , 126611
Identification of a novel allosteric GLP-1R antagonist HTL26119 using structure-based drug design
- 1 October 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (20) , 126611
Identification of a novel allosteric GLP-1R antagonist HTL26119 using structure-based drug design
- 30 October 2018
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 9 (12) , 1164-1169
3,5-Disubstituted-indole-7-carboxamides as IKKβ Inhibitors: Optimization of Oral Activity via the C3 Substituent
IκκB Kinase β (IKKβ or IKK2) is a key regulator of nuclear factor kappa B (NF-κB) and has received attention as a therapeutic target. Herein we report on the optimization of a series of 3,5-disubstituted-indole-7-carboxamides for oral activity. In doing so we focused attention on potency, ligand efficiency (LE), and physicochemical properties and have identified compounds 24 and (R)-28 as having robust in-vivo activity.
- 30 October 2018
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 9 (12) , 1164-1169
3,5-Disubstituted-indole-7-carboxamides as IKKβ Inhibitors: Optimization of Oral Activity via the C3 Substituent
IκκB Kinase β (IKKβ or IKK2) is a key regulator of nuclear factor kappa B (NF-κB) and has received attention as a therapeutic target. Herein we report on the optimization of a series of 3,5-disubstituted-indole-7-carboxamides for oral activity. In doing so we focused attention on potency, ligand efficiency (LE), and physicochemical properties and have identified compounds 24 and (R)-28 as having robust in-vivo activity.
- 18 February 2018
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (1) , 207-222
Structure-Based Optimization Strategies for G Protein-Coupled Receptor (GPCR) Allosteric Modulators: A Case Study from Analyses of New Metabotropic Glutamate Receptor 5 (mGlu5) X-ray Structures
Two interesting new X-ray structures of negative allosteric modulator (NAM) ligands for the mGlu5 receptor, M-MPEP (3) and fenobam (4), are reported. The new structures show how the binding of the ligands induces different receptor water channel conformations to previously published structures. The structure of fenobam, where a urea replaces the acetylenic linker in M-MPEP and mavoglurant, reveals a binding mode where the ligand is rotated by 180º compared to a previously proposed docking model. The need for multiple ligand structures for accurate GPCR structure-based drug design is demonstrated by the different growing vectors identified for the head groups of M-MPEP and mavoglurant and by the unexpected water mediated receptor interactions of a new chemotype represented by fenobam. The implications of the new structures for ligand design are discussed, with extensive analysis of the energetics of the water networks of both pseudo-apo and bound structures providing a new design strategy for allosteric modulators.
- 18 February 2018
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (1) , 207-222
Structure-Based Optimization Strategies for G Protein-Coupled Receptor (GPCR) Allosteric Modulators: A Case Study from Analyses of New Metabotropic Glutamate Receptor 5 (mGlu5) X-ray Structures
Two interesting new X-ray structures of negative allosteric modulator (NAM) ligands for the mGlu5 receptor, M-MPEP (3) and fenobam (4), are reported. The new structures show how the binding of the ligands induces different receptor water channel conformations to previously published structures. The structure of fenobam, where a urea replaces the acetylenic linker in M-MPEP and mavoglurant, reveals a binding mode where the ligand is rotated by 180º compared to a previously proposed docking model. The need for multiple ligand structures for accurate GPCR structure-based drug design is demonstrated by the different growing vectors identified for the head groups of M-MPEP and mavoglurant and by the unexpected water mediated receptor interactions of a new chemotype represented by fenobam. The implications of the new structures for ligand design are discussed, with extensive analysis of the energetics of the water networks of both pseudo-apo and bound structures providing a new design strategy for allosteric modulators.
- 14 November 2016
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 17 (1) , 71-78
Potential for the Rational Design of Allosteric Modulators of Class C GPCRs
Class C G protein-coupled receptors encompass a range of promising therapeutic targets for a variety of diseases, yet to date only two members of this sub-family of GPCRs have been drugged. Recent advances in structural biology have revealed the X-ray crystallographic structures of allosteric ligands bound to two Class C metabotropic glutamate (mGlu) receptors, mGlu1 and mGlu5. Herein, we review how this information can be leveraged to help understand some of the historical challenges of mGlu receptor allosteric modulator drug discovery, and discuss how the structural enablement can be prospectively used for structure-based drug discovery approaches across Class C GPCR targets in general.
- 14 November 2016
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 17 (1) , 71-78
Potential for the Rational Design of Allosteric Modulators of Class C GPCRs
Class C G protein-coupled receptors encompass a range of promising therapeutic targets for a variety of diseases, yet to date only two members of this sub-family of GPCRs have been drugged. Recent advances in structural biology have revealed the X-ray crystallographic structures of allosteric ligands bound to two Class C metabotropic glutamate (mGlu) receptors, mGlu1 and mGlu5. Herein, we review how this information can be leveraged to help understand some of the historical challenges of mGlu receptor allosteric modulator drug discovery, and discuss how the structural enablement can be prospectively used for structure-based drug discovery approaches across Class C GPCR targets in general.
- 12 August 2015
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 58 (16) , 6653-6664
Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile)
Fragment screening of a thermostabilized mGlu5 receptor using a high-concentration radioligand binding assay enabled the identification of moderate affinity, high ligand efficiency (LE) pyrimidine hit 5. Subsequent optimization using structure-based drug discovery methods led to the selection of 25, HTL14242, as an advanced lead compound for further development. Structures of the stabilized mGlu5 receptor complexed with 25 and another molecule in the series, 14, were determined at resolutions of 2.6 and 3.1 Å, respectively.
- 12 August 2015
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 58 (16) , 6653-6664
Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile)
Fragment screening of a thermostabilized mGlu5 receptor using a high-concentration radioligand binding assay enabled the identification of moderate affinity, high ligand efficiency (LE) pyrimidine hit 5. Subsequent optimization using structure-based drug discovery methods led to the selection of 25, HTL14242, as an advanced lead compound for further development. Structures of the stabilized mGlu5 receptor complexed with 25 and another molecule in the series, 14, were determined at resolutions of 2.6 and 3.1 Å, respectively.
- 30 March 2015
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 6 (5) , 947-955
Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties
A novel series of potent, selective, and orally efficacious dual antagonists of the orexin receptors has been investigated, resulting in the identification of lead compound 27 (HTL6641). Comprehensive data for 27 are presented, including in vivo PK parameters, confirmation of receptor occupancy through ex vivo binding and efficacy in a rat sleep model. A key feature of the series is a short dissociation half-life, measured by surface plasmon resonance (SPR) using stabilized receptors, and confirmed by radioligand-binding experiments. Based on a consideration of the requirements for a potential treatment for insomnia, compound 27 was identified as having the best balance of properties from the chemical series.
- 30 March 2015
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 6 (5) , 947-955
Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties
A novel series of potent, selective, and orally efficacious dual antagonists of the orexin receptors has been investigated, resulting in the identification of lead compound 27 (HTL6641). Comprehensive data for 27 are presented, including in vivo PK parameters, confirmation of receptor occupancy through ex vivo binding and efficacy in a rat sleep model. A key feature of the series is a short dissociation half-life, measured by surface plasmon resonance (SPR) using stabilized receptors, and confirmed by radioligand-binding experiments. Based on a consideration of the requirements for a potential treatment for insomnia, compound 27 was identified as having the best balance of properties from the chemical series.
- 18 December 2013
- Published by Wiley in ChemMedChem
- Vol. 9 (2) , 256-275
Structure‐Based and Fragment‐Based GPCR Drug Discovery
G protein‐coupled receptors (GPCRs) are an important family of membrane proteins; historically, drug discovery in this target class has been fruitful, with many of the world’s top‐selling drugs being GPCR modulators. Until recently, the modern techniques of structure‐ and fragment‐based drug discovery had not been fully applied to GPCRs, primarily because of the instability of these proteins when isolated from their cell membrane environments. Recent advances in receptor stabilisation have facilitated major advances in GPCR structural biology over the past six years, with 21 new receptor targets successfully crystallised with one or more ligands. The dramatic increase in GPCR structural information has yielded an increased use of structure‐based methods for hit identification and progression, which are reviewed herein. Additionally, a number of fragment‐based drug discovery techniques have been validated for use with GPCRs in recent years; these approaches and their use in hit identification are reviewed.
- 18 December 2013
- Published by Wiley in ChemMedChem
- Vol. 9 (2) , 256-275
Structure‐Based and Fragment‐Based GPCR Drug Discovery
G protein‐coupled receptors (GPCRs) are an important family of membrane proteins; historically, drug discovery in this target class has been fruitful, with many of the world’s top‐selling drugs being GPCR modulators. Until recently, the modern techniques of structure‐ and fragment‐based drug discovery had not been fully applied to GPCRs, primarily because of the instability of these proteins when isolated from their cell membrane environments. Recent advances in receptor stabilisation have facilitated major advances in GPCR structural biology over the past six years, with 21 new receptor targets successfully crystallised with one or more ligands. The dramatic increase in GPCR structural information has yielded an increased use of structure‐based methods for hit identification and progression, which are reviewed herein. Additionally, a number of fragment‐based drug discovery techniques have been validated for use with GPCRs in recent years; these approaches and their use in hit identification are reviewed.